Nina M. Berkowitz - Concepedia

Author

Nina M. Berkowitz

National Institute of Allergy and Infectious Diseases

Also Known As

Brenda Larkin, Jennifer Munt, Maria C. Burgos Florez, Nina Berkowitz, Nina M Berkowitz, Nina M. Berkowitz, Thuy A. Nguyen

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

National Institute of Allergy and Infectious Diseases National Institutes of Health Frederick National Laboratory for Cancer Research Leidos (United States)United States Public Health Service Commissioned Officers Association

About

Nina M. Berkowitz is an author at National Institute of Allergy and Infectious Diseases specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	738
2	Immunology	9	9	738
3	Pharmacology	2	2	140
4	Epidemiology	1	1	125
5	Pathology	1	1	37

Nina M. Berkowitz

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
A proof of concept for structure-based vaccine design targeting RSV in humans Michelle C. Crank, Tracy J. Ruckwardt, Man Chen, Science	2019	323
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials Martin R. Gaudinski, Katherine V. Houser, Kaitlyn M. Morabito, The Lancet	2017	298
Chimpanzee Adenovirus Vector Ebola Vaccine Julie E. Ledgerwood, Adam DeZure, Daphne A. Stanley, New England Journal of Medicine	2014	281
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection Kirsten E. Lyke, Andrew S. Ishizuka, Andrea A. Berry, Proceedings of the National Academy of Sciences	2017	245
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial Katherine V. Houser, Grace Chen, Cristina Carter, Nature Medicine VaccinologyVaccine SafetyVaccinationCross-protectionVaccine Development	2022	153
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial Hannah Kibuuka, Nina M. Berkowitz, Monica Millard, The Lancet VaccinologyVaccine SafetyVaccinationPhase 1BVaccine Development	2014	125
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study Martin R. Gaudinski, Emily E. Coates, Laura Novik, The Lancet VaccinationOpen-label Phase 1Vaccine TargetImmunologyAntiviral Drug Development	2019	123
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria Richard L Wu, Azza H. Idris, Nina M. Berkowitz, New England Journal of Medicine	2022	114
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial Martin R. Gaudinski, Katherine V. Houser, Nicole A. Doria‐Rose, The Lancet HIV ImmunologyPharmacologyTherapeutic EfficacyAntibody ScreeningAntibody Engineering	2019	105
Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability Outcomes Grace Chen, Emily E. Coates, Sarah H. Plummer, JAMA	2020	103

Page 1